Tag: DBV Technologies

Viaskin Peanut Patch: Lasting Response After Three Years

Pediatric patients responded with a favorable safety profile and no serious adverse effects.

Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial

The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.
DBV Patch Closeup

Study: EPIT (Skin Patch) Therapy Provides Sustained Protection Against Anaphylaxis

The unique immune communication between skin and gastrointestinal tract can be used to generate long-lasting protection from food allergies.

Nestlé Partners with DBV to Develop Milk Allergy Test

The world's largest food business forays into allergy diagnostic services to help sell infant formula.

Viaskin Peanut, Milk and Egg Patch Therapies: Promising News from the...

We are cautiously optimistic that a safe, effective, easy to administer treatment for food allergy may be on the horizon.

Breakthrough Food Allergy Therapies and the Big Business Behind Them

What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.

Viaskin Milk Patch Receives Positive Recommendation to Proceed to Phase II

The board overseeing the Phase I study of the milk allergy therapy found no safety concerns.

Peanut Patch Receives FDA's Breakthrough Therapy Designation

The Viaskin Peanut patch received the BT designation after a positive Phase IIb trial.